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Molecular genetics of Aiport syndrome. Alport syndrome is a progres-
sive hereditary kidney disease characterized by hematuria, sensorineu-
ral hearing loss and ocular lesions with structural defects in the
glomerular basement membrane (GBM). The gene frequency has been
estimated to be 1:5000. The disease is primarily X chromosome-linked,
but autosomal forms have also been reported. The X-linked form has
been shown to be caused by mutations in a recently identified a5(IV)
collagen chain gene (COL4A5). We have isolated eDNA clones for
providing the entire primary structure of the human a5(IV) chain. The
gene has been located to the Xq22 region. Using antibodies against
synthetic peptides, the a5(IV) chain was shown to be located in the
kidney only in the glomerular basement membrane. Thus far, the
exo1.-.tron structure has been determined for a large portion of the
gene which probably has a size of over 200 kb. Numerous different
mutations have been identified in the COL4A5 gene. The mutations
include single base mutations, large deletions and other major rear-
rangements such as inversion and duplication. The consequences of the
mutations observed can be considered sufficient to cause structural and
functional defects in the type IV collagen molecule and, therefore, also
the GBM network. This, in turn can explain the disruption of the GBM
and hematuria occurring in these Alport patients. Alport syndrome is
the first genetic basement membrane and kidney disease whose gene
has been cloned. These recent results have enabled the development of
antibodies and DNA probes for accurate diagnosis of Alport syndrome.
Clinical features of Alport syndrome
Alport syndrome is an inherited progressive kidney disease
with an estimated gene frequency of 1:5000 [1, 2]. The disease
is characterized by hematuria and terminal renal failure, often
accompanied by familial hearing loss and ocular lesions such as
lenticonus [2]. It is usually inherited as an X chromosome-
linked dominant trait, but autosomal forms have also been
described. Clinically, Alport syndrome patients have recurrent
microscopic or gross hematuria, as early as in childhood, earlier
in males than females. The hearing loss is sensorineural and
primarily affects high tones. Electron microscopy usually
shows thinning and thickening and splitting of the glomerular
basement membrane (GBM) into thin layers, with accumulation
of electron dense particles. Anterior lenticonus, a peculiar
change of lens shape in which the anterior lens pole shows a
conical deformation, is also frequently observed in Alport
patients. Absence of family history in Alport syndrome is
present in about 15% of the cases. These may represent new
mutations [2, 31. The diagnosis of Alport syndrome has been
made based on clinical findings, but there has been some
confusion amongst clinicians about criteria and definitions.
Atkin, Gregory and Border [2] have classified the disease into
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six types according to inheritance, end-stage renal disease
(ESRD) and occurrence of deafness. In the juvenile Alport
syndrome the onset of ESRD occurs at or under 25 years of age.
According to this classification, type I is classic juvenile Alport
with deafness, type II is X-linked juvenile with deafness, type
III is X-linked adult form with deafness, type IV is X-linked
adult without deafness, type V is autosomal with deafness and
thrombocytopathy, and type VI is autosomal with deafness.
This classification has recently been revised to contain seven
different types and several subtypes (Atkin, personal commu-
nication). Flinter et al [4] proposed that Alport syndrome can be
diagnosed if at least three of the four following criteria are
fulfilled: (i) positive family history of hematuria/chronic renal
failure; (ii) electron microscopic evidence on renal biopsy of
Alport syndrome; (iii) progressive high tone sensorineural deaf-
ness; and (iv) characteristic eye signs. In the light of recent
research, both classification criteria have, however, their draw-
backs and it seems obvious that diagnosis of the disease will
have to be made in the future on the basis of both clinical
phenotypes and molecular defects. The defective gene in
X-linked Alport was previously mapped by the use of chromo-
some markers to the middle of the long arm of the X chromo-
some [4—6]. It had previously been suggested, based on the
electron microscopic findings, that the affected gene coded for
a type IV collagen a chain since this collagen type forms the
structural network of basement membranes [7]. This hypothesis
proved right for the X chromosome-linked disease, where
mutations have been found in the a5(IV) collagen gene [81. The
gene(s) affected in autosomal forms of Alport syndrome is
38
unknown.
Type IV collagen
The existence of type IV collagen was first demonstrated
1971 when it was isolated from the renal GBM [91. As are all
collagens, type IV collagen is composed of three a chains that
form a triple-helical molecule [7]. In recent years, it has been
demonstrated that type IV collagen is a more complicated
protein than previously thought. In addition to the two major
and ubiquitous subunit components, al(IV) and a2(IV), addi-
tional minor components, a3(IV), a4(IV) and a5(IV) have been
identified and characterized [10—18]. The type IV collagen a
chains, which have molecular weights of 170 to 185 kDa,
contain long collagenous Gly-X-Y-repeat sequences which are
interrupted between 21 to 23 times by noncollagenous se-
quences. Additionally, each a chain contains an about 26 to 28
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Fig. 1. Illustration of the primary structure of the a5(IV) collagen chain. The signal peptide (residues 1-27) is indicated by a black pattern. The
Gly-X-Y-repeat containing collagenous domain (residues 28-1,456) is shown by a white pattern with the 22 noncollagenous interruptions depicted
by shaded boxes. The C-terminal end NC domain (residues 1,457-1,685) is shown by a shaded pattern.
kDa carboxyl terminal noncollagenous domain (NC domain).
The large number of type IV collagen a chain subunits demon-
strates that this triple-helical protein must be present in several
isoforms indicating versatile and tissue specific functions. How-
ever, the major ubiquitous isoform is a heterotrimer composed
of al(IV) and a2(IV) chains in a 2:1 ratio [7]. Both these chains
have been completely sequenced from humans [19—21] and their
genes have been localized to chromosome 13 [22—24]. Partial
sequences of the bovine a3(IV) and a4(IV) chains have been
obtained from proteolytic peptides and cDNA clones [10—12,
14]. Furthermore, cDNA clones have been isolated for the
human a3(IV) and a4(IV) chains and their genes have been
assigned to chromosome 2 [13, 15]. Also, the complete se-
quence of the a5(IV) chain has been determined [16—18]. It is
not known into what kinds of molecules the minor chains
a3(IV), a4(IV) and a5(IV), are incorporated. After being se-
creted out of the cell, the triple-helical type IV collagen
molecules assemble into a omp1ex network [7] so that disulfide
bonds are formed between the carboxyl terminal noncollage-
nous domains of two molecules (monomers) and the amino
termini of four molecules. Additionally, the molecules are
believed to align laterally to each other to form a stronger
structure [25].
The aS chain of type IV collagen
The a5(IV) chain is the most recently identified member of
the type IV collagen a chain family. Thus far, there are no
reports on the characterization of the a5(IV) chain protein
itself. However, the entire primary structure of the human
a5(IV) chain has now been elucidated from overlapping cDNA
clones. Hostikka et al described clones providing about 50% of
the carboxyl terminal end of the chain [16] and Pihiajaniemi,
Pohjalainen and Myers cDNA clones yielding the sequence also
for the entire collagenous domain [17]. cDNA clones coding for
the missing amino terminal end have recently been accom-
plished through the generation of primer-extended eDNA
clones [18]. The cDNA-derived amino acid sequence demon-
strates that the human a5(IV) chain is synthesized as a 1685-
residue polypeptide containing a putative 27-residue signal
peptide, 1429 residues of a collagenous domain and a 229-
residue carboxyl terminal noncollagenous domain (Fig. 1). The
collagenous domain has 22 interruptions of 1 to 11 amino acid
residues in length. All the interruptions, except interruption 13,
coincide with interruptions in the al(IV) chain. Overall se-
quence comparison demonstrates that the a5(IV) and al(IV)
chains are quite homologous, as opposed to the a2(IV) chain
which has less similarity with the other two. A comparison of
the human a5(IV), al(IV) and a2(IV) chains is illustrated in
a5 al a2 a3
Amino acids 1685 1669 1712
Signal peptide 27 27 36
Helix domain 1429 1413 1449
NC-domain 229 229 227
Number of interruptions in
helical domain
[Refs. 12, 13, 16—21]
22 21 23
Table 1. Since the a5(IV) chain has not been purified and
characterized at the protein level, it is not known whether it is
assembled into an [aS(IV)]3 homotrimer Or into heterotrimers
together with some of the other type IV collagen a chains.
The amino acid sequence of the al(IV), a2(IV) and a5(IV)
chains shows extensive sequence similarity, indicating that
polyclonal antibodies made against individual chains might
easily cross react. In fact, it is impossible to find a 10-residue
sequence unique for the a5(IV) chain. However, one peptide
containing the sequence, Ser-Asp-Met-Phe-Ser-Lys-Pro-Gln-
Ser-Glu, from the end of the NC domain has been used
successfully as an antigen for generating antibodies against the
a5(IV) chain [16]. The antisera obtained against this peptide,
which actually has 50% sequence identity with the correspond-
ing region of the al(IV) chain, do not cross react with the
al(IV) or a2(IV) chains. Immunostaining analysis on a number
of human tissues [16, 26] has revealed that the a5(IV) chain has
quite restricted tissue distribution [16, 26]. Importantly, the
a5(IV) chain seems to be located in the kidney only in the
glomerular basement membrane (Fig. 2) which may explain the
generation of Alport syndrome by mutations in the COL4AS
gene. At present, it has not been possible to obtain proper
immunostaining of the BM in the inner ear, another tissue
possibly affected in Alports syndrome.
Type IV collagen aS chain gene (COL4A5)
The human COL4A5 gene has been located to the q22 region
of chromosome X by hybridization of cDNA probes to DNA
from somatic cell hydrids and by in situ hybridization (Fig. 3)
[16]. The COL4A5 gene is the only basement membrane gene so
far which has been localized on chromosome X. The genes for
the other human type IV collagen a chains COL4A1 and
COL4A2 are located on chromosome 13 [16, 22—241 and
COL4A3 and COL4A4 are on chromosome 2 [13, 151. The
entire exon-intron structure of the COL4A5 gene has been
elucidated [27, 381. The gene contains 51 exons which all,
except nine, are identical in size to those of COL4A5 [281. In
Table 1. Comparison of mammalian type IV collagen a chainsa
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Fig. 2. linmunostaining of a frozen section human renal glomerulus
with a5(JV) collagen chain specific antibodies, The reaction can be seen
in the GBM whereas the mesangium is negative.
contrast, the exon size pattern of the COL4A2 gene differs
considerably from both the COL4A5 and COL4A1 genes. For
example, the NC domain is encoded by three exons in the
COL4A2 gene, but by five exons in the two other genes [27—291
The intron locations in the COL4A2 gene are conserved,
however. In the collagen domain coding sequences, the exon
sizes and exon-intron boundaries of the COL4A2 gene are
frequently different from the COL4A5 and COL4A1 genes. The
finding of closely located pairs of type IV collagen genes on
both chromosomes 13 and 2 raises the intriguing question
whether there is a second type IV collagen a chain gene on
located chromosome X, possibly in a close proximity to
COL4A5. The characterization of the COL4A5 gene locus and
its adjacent regions may soon give an answer to that question.
Mutations in the COL4A5 gene in X chromosome-linked Alport
syndrome
The assignment of the COL4A5 gene to Xq22, and demon-
stration of the GBM-specific location of the a5(IV) chain in the
kidney, made the COL4A5 gene a candidate gene for Alport
syndrome. This was also shown to be the case in some patients
with the X-linked form of Alport syndrome. To date, a number
of mutations have been found in the COL4A5 gene in kindreds
with Alport syndrome (Table 2). Some mutations are single
base mutations which can be expected to render the aS(IV)
chain containing type IV collagen molecules malfunctional.
Other mutations involve small or large gene deletions which
would result in the complete absence of the a5(IV) chain or the
generation of shortened chains. To understand the potential
consequences of mutations in the COL4A5 gene, it is essential
to understand some basic properties of collagenous proteins
and, in particular, type IV collagen. As described above, the
basement membrane (BM) structure network is formed by
end-to-end and laterally aligned triple-helical type IV collagen
molecules that are bound to each other by covalent bonds.
Mutations in any type IV collagen a chain gene could result in
changes that affect: (i) the formation of the primary transcript,
(ii) post-transcriptional modification of nascent a chains, (iii)
the assembly and folding of three a chains into a triple-helical
molecule, or (iv) formation of cross-links between individual
triple-helical molecules. The mutations can be expected to
cause manifestations primarily in BMs where the protein is
particularly abundant, as is the case for the a5(IV) chain which
is mainly found in the GBM. Mutations in type IV collagen
genes might lead to alterations in the proteins and tissues
containing them, as has been shown for mutations in genes for
fibrillar collagens (types I, II and III). For instance, over 70
different mutations have been identified in the type I procolla-
gen genes in osteo genesis imperfecta, a disease characterized
by fragile bones [30]. Also mutations in the cartilage-specific
type II procollagen al chain gene (COL4A1) have been identi-
fied in diseases affecting cartilage [30] and mutations in the type
III procollagen al chain gene (COL3A1) have been shown to
result in the Ehiers-Danlos syndrome and familial aneurysms
[31]. The mutations in these genes vary from large deletions to
a variety of point mutations in different regions of the genes.
The different mutations in the fibrillar collagen genes generate a
large variety of phenotypes, both lethal and mild. It is interest-
ing that, despite extensive knowledge about the proteins, it is
particularly difficult and often even impossible to predict the
phenotype generated by some point mutations. For example,
substitution of two closely located glycine residues of the a 1(I)
chain can result in different phenotypes, one being lethal and
the other causing mild disease [30].
As is the case for mutations in the genes of fibrillar collagens,
it is difficult to predict the consequences of mutations in the
COL4A5 collagen gene in Alport syndrome; since there are no
studies so far on the protein itself in these cases, one cannot
state for sure whether the mutations and their resulting changes
in the protein actually cause the Alport phenotype. However,
most kindreds studied are large and the mutations have, in most
cases, been shown to segregate with the disease. As has been
shown for the mutations in type I, II and III collagen genes, the
wide spectrum of mutations in the COL4A5 gene seems to
cause a variety of phenotypes which are difficult to predict.
Interestingly, some mutations result in disease which does not
even fulfill the currently used diagnostic criteria for Alport
syndrome. Some of the mutations identified and the resulting
phenotypes are described in the following text and Table 3.
Several single base mutations have now been identified.
These mutations are scattered all over the gene changing amino
acid residues both in the collagenous and noncollagenous
domains (Fig. 4). One of the two mutations first described is a
point mutation in the COL4A5 gene in a large Utah kindred P
which carries type III Alport syndrome [8, 32]. Variant PstI and
BglII restriction sites were found in the 3 end of the gene. The
mutation was shown to change the TGT codon of cysteine-1564
to the TCT codon for serine, thereby creating new PstI and
BglII restriction sites. The substituted amino acid represents
one of twelve conserved cysteine residues located in the NC
domain of the a5(IV) chain, and it is believed to be crucial for
maintaining the correct conformation of the NC domain and for
the formation of intermolecular cross links. Notwithstanding
the existence of actual protein data, the mutation can be
surmised to be sufficient to affect intermolecular cross linking
and, therefore, lead to the disruption of the GBM observed by
electron microscopy and which leads to hematuria of the
affected individuals. A second point mutation was identified in
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Fig. 3. Chromosome localization of the COL4A5 gene showing pattern of silver grain distribution after in situ hybridization with a
COL4A5-specfIc DNA probe to metaphase and prometaphase chromosomes [16]. A. Distribution of autoradiographic silver grains showing significant
accumulation over the chromosome Xq region. B. Grain distribution over chromosome X. The majority of silver grains are seen at the q22 region.
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Table 2. Mutations in the COL4A5 collagen gene and phenotypes in Alport syndrome
Mutation
Phenotype
Kidney
transplant
Anti-GBM
nephritis Reference
ESRD
juvenile
onset
adult
Hearing
loss
Ocular
lesions
GBM
splitting
Point mutations
Gly 325 - Arg + + — + — [35]
Gly 325 — Glu + — — + [39]
Gly 521 - Cys + + — nd + — [18]
Gly 1143 — Asp + — + + [33]
Pro 1517 - Thr + + — nd [40]
Trp 1538 — Ser + — — + + — [34]
Arg 1563 —* GIn + + (-1-) + + — [40, 41]
Arg 1563 — stop codon + + — nd [41]
Cys 1564 —* Ser + + — + + [8, 32]
Splice mutations
elimination of exon 38 [42]
Deletions
exons 42—47 + + — nd — [8]
13 kb from 3'-end of gene + + — + + [36]
large deletion from 3'-end of gene + + — + + + [34]
deletion of 5'-end of exon 1 + + + — [43]
upstream
deletion of several 5' exons and — + + [43]
upstream
deletion of 5' exon 1 and + — + + + [43]
upstream
>'38 kb in 5'-end (+) + — nd [44]
large deletion in 3'-end + + — + + + [40]
exons 38—51 4- + + nd [45]
entire gene + + + nd + + [45]
Insertion/duplication/deletion
part of 3'-end of gene + + + + + — [36]
Duplication/inversion
part of 3'-end of gene + 4- 4- + + — [36]
Abbreviation is: nd, not determined.
Fig. 4. Consequences of known single base mutations in the COL4A5 gene on the a5(IV) collagen chain in d/ferent Alport kindreds.
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Fig. S. Consequences of a deletion mutation in the COL4A5 gene in an Alport syndrome patient [8]. There is an in frame loss of exons 42—47
(counted from 3'-end of the gene) resulting in the loss of 193 amino acid residues from the collagenous domain and 47 residues from the MC domain
of the aS(IV) chain.
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an Alport patient with juvenile onset of ESRD without hearing
loss or eye lesions [33]. Electron microscopy revealed splitting
of the lamina densa in the GBM. DNA sequencing demon-
strated a single base change G —* A, converting the codon GGC
of glycine-l 143 to GAC for aspartate (Fig. 5). Additionally, the
mutation abolished an MspI site. The mutation which leads to
the removal of a glycine in the center of a 38 Gly-X-Y-repeat
collagenous sequence is likely to be sufficient to destroy the
triple helix conformation and, thereby can cause abnormal
GBM structure. This mutation is particularly interesting be-
cause the resulting phenotype does not fulfill the criteria for the
above-mentioned classifications of Alport syndrome. This em-
phasizes the need for reclassification of Alport syndrome and
indicates that the disease is underdiagnosed. A third point
mutation [34] replaced an evolutionarily conserved trypto-
phane-1538 in the NC domain by serine (Fig. 5). A fourth point
mutation involves the conversion of glycine-521 to cysteine in a
patient with juvenile form of Alport syndrome accompanied by
sensorineural deafness (Fig. 5) [18]. The mutation creates a new
Hindlil site which can serve as a disease marker in this kindred.
The cysteine is likely to cause disruption of the triple helix in
this region and to generate abnormal intra- and interchain
disulfide bonds. A fifth single base mutation caused the conver-
sion of glycine 325 to arginine [35]. The affected males of this
family have developed end-stage renal disease between 22 and
76 years of age. They also have deafness but no ocular
abnormalities. Abnormal GBM with abnormal thinning and
thickening and splitting of the lamina densa is also found.
A number of mutations primarily involving deletions but also
other major rearrangements have also been found in patients
with Alport syndrome. The first deletion to be characterized
involved a 15kb deletion containing exons 42 to 47 as counted
from the 5' end [8]. This "in frame" deletion would lead to the
loss of 240 amino acid residues from the a5(IV) chain, 193
residues from the carboxyl terminal end of the collagenous
domain and 47 residues from the NC domain (Fig. 5). The
resulting polypeptide would certainly not be able to participate
in a functional type IV collagen molecule, be it a homo- or
heterotrimer form. Other deletions have been characterized in a
kindred with type II Alport syndrome with juvenile onset
end-stage renal disease: hearing loss and GBM splitting [34].
The patient received a kidney transplant, but developed de
novo anti-GBM nephritis within a year. The COL4A5 gene of
this patient was shown to have a large deletion removing close
to one-half of the gene from the 3' end. The exact location of the
5' end breaking point is not yet clear. This mutation is interest-
ing because of the phenotype it generates. It appears that a
deletion resulting in the loss of the carboxyl terminal end of the
protein causes the patient to recognize the transplant's a5(IV)
chain as a foreign protein. These observations indicate that it
may become possible in the future to select patients who are not
likely to benefit from transplantation [34]. In addition to the
above, Boye et al [36] have recently reported major rearrange-
ments including deletion, insertion/deletion and partial duplica-
tion, in the COL4A5 gene in three patients with Alport syn-
drome [37]. The breakpoints in the gene have not been
determined.
Very recently, several new mutations have been reported in
the COL4A5 gene [39—45] and they have been included in Table
2. It is conceivable that the majority, if not all the cases, of
X-linked Alport syndrome will prove to involve mutations in
the COL4A5 gene. However, there is a possibility that in
another type IV collagen, a chain gene is located on chromo-
some X which might be affected by the disease.
Autosomal forms of Alport syndrome
Autosomally inherited forms of Alport syndrome have been
reported although they are much more rare than the X-linked
forms. According to the classification of Atkins, Gregory and
Border [2], these cases belong to type V Alport syndrome, with
deafness and thrombocytopathy, and type VI with deafness. In
both phenotypes, the patients develop hematuria, end-stage
renal failure and disrupted GBM structure. Nothing is known
about the chromosome loci or defective gene(s) in these phe-
notypes. However, in analogy with the X chromosome-linked
forms, the genes of the other minor type IV collagen chains,
COL4A3 or COL4A4 on chromosome 2, are clearly candidate
genes. The recent cloning of the human genes now allows this
question to be explored.
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